Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
The last earnings update was 53 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Madrigal Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Madrigal Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Madrigal Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Madrigal Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Madrigal Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Madrigal Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Madrigal Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Madrigal Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
Madrigal Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Madrigal Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Paul A. Friedman, M.D., has been Chairman and Chief Executive Officer of Madrigal Pharmaceuticals, Inc. since July 22, 2016 and served as its President since July 22, 2016. Dr. Friedman is Co-Owner of SQN, LLC. He serves as a Partner of Vilicus Ventures, LLC. Dr. Friedman is a Cardiologist and Professor at Mayo Clinic. He is a Professor of Medicine and a consultant of cardiovascular electrophysiology. He has more than 20 years of experience in the pharmaceutical industry. He served as an Executive Chairman of Cerulean Pharma Inc. since October 29, 2014 until June 2016. He served as the Chief Executive Officer of Incyte Corporation from November 2001 to January 13, 2014 and served as its President from May 2004 to January 13, 2014. where he led a transformation of the business from genomics to a therapeutic focus establishing its foundation as a leader in oncology. From 1998 to October 2001, Dr. Friedman served as the President of DuPont Pharmaceuticals Research Laboratories. From 1994 to 1998, he served as the President of Research and Development of The DuPont Merck Pharmaceutical Company. From 1991 to 1994, he served as Senior Vice President at Merck Sharp & Dohme Research Laboratories. He held executive and R&D positions at Merck Research Laboratories. From 1985 to 1991, he held several executive positions at Merck. From 1974 to 1985, he served as an Associate Professor of Medicine and Pharmacology at Harvard Medical School. He has been Director at Alexion Pharmaceuticals, Inc. since September 14, 2017. He has been a Director of Cerulean Pharma Inc. since January 2014 until 2017 and Durata Therapeutics, Inc. since May 16, 2013 until 2014. He has been a Non Executive Director of Gliknik, Inc. since February 25, 2013. He has been an Independent Director of Navitor Pharmaceuticals, Inc. since June 2015. He has been a Director of Incyte Corporation since November 2001. He has been a Member of Clinical and Scientific Advisory Board of Verastem, Inc. since May 2017 and served as its Independent Director since May 2014 until April 27, 2017. Dr. Friedman served as a Director of Synta Pharmaceuticals Corp. since March 2014 until 2016. He served as a Director of Auxilium Pharmaceuticals Inc. from June 2010 to January 29, 2015. He served as a Director of Sirtris Pharmaceuticals, Inc. from March 2008 to June 2008. He served as a Director of Bausch & Lomb Incorporated from June 2004 to October 2007. He is a Diplomate of the American Board of Internal Medicine and a Member of the American Society of Clinical Investigation. He is the author of over 100 scientific publications. He has over 40 biomedical patents and has authored over 300 scientific publications, including books, book chapters and original articles. He is the reviewer or editor of over 15 influential medical journals and directs national and international medical education meetings. He has been the principal investigator of large, international, multicenter trials. He has also been the recipient of federal and regional research awards to assess and develop new healthcare technologies. He is the Vice Chair of Academic Affairs and Faculty Development at the Mayo Clinic. He is the Vice Chair of the Division of Cardiovascular Medicine at the Mayo Clinic. Dr. Friedman received an M.D. Degree from Harvard Medical School in 1969 and B.S. degree in Biology from Princeton University, Princeton, New Jersey, in 1964.
Paul's compensation has been consistent with company performance over the past year.
Paul's remuneration is about average for companies of similar size in Germany.
Chairman & CEO
Senior VP & CFO
Senior Vice President of Clinical Management
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Madrigal Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.